M J Spriggs1, H Kettner2, R L Carhart-Harris2. 1. Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK. m.spriggs@imperial.ac.uk. 2. Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
Abstract
PURPOSE: Psychedelic therapy is showing promise for a broad range of mental health conditions, indicative of a transdiagnostic action. While the efficacy of symptom-focused treatments for eating disorders (EDs) is limited, improved mental health and psychological wellbeing are thought to contribute to greater treatment outcomes. This study provides the first quantitative exploration of the psychological effects of psychedelics in those reporting an ED diagnosis. METHODS: Prospective, online data were collected from individuals planning to take a psychedelic drug. Twenty-eight participants reporting a lifetime ED diagnosis completed measures of depressive symptomology (Quick Inventory of Depressive Symptomology; QIDS-SR16) and psychological wellbeing (Warwick-Edinburgh Mental Wellbeing Scale; WEMWBS) 1-2 weeks before, and 2 weeks after a psychedelic experience. Twenty-seven of these participants also completed a measure of emotional breakthrough [Emotional Breakthrough Inventory (EBI)] in relation to the acute psychedelic experience. RESULTS: Bayesian t tests demonstrated overwhelming evidence for improvements in depression and wellbeing scores following the psychedelic experience. Marginal evidence was also found for a correlation between emotional breakthrough and the relevant mental health improvements. CONCLUSION: These findings provide supportive evidence for positive psychological aftereffects of a psychedelic experience that are relevant to the treatment of EDs. It is hoped that this will encourage further research and will bolster initiatives to directly examine the safety and efficacy of psychedelic assisted therapy as a treatment of EDs in future clinical trials. LEVEL OF EVIDENCE: Level III, cohort study.
PURPOSE: Psychedelic therapy is showing promise for a broad range of mental health conditions, indicative of a transdiagnostic action. While the efficacy of symptom-focused treatments for eating disorders (EDs) is limited, improved mental health and psychological wellbeing are thought to contribute to greater treatment outcomes. This study provides the first quantitative exploration of the psychological effects of psychedelics in those reporting an ED diagnosis. METHODS: Prospective, online data were collected from individuals planning to take a psychedelic drug. Twenty-eight participants reporting a lifetime ED diagnosis completed measures of depressive symptomology (Quick Inventory of Depressive Symptomology; QIDS-SR16) and psychological wellbeing (Warwick-Edinburgh Mental Wellbeing Scale; WEMWBS) 1-2 weeks before, and 2 weeks after a psychedelic experience. Twenty-seven of these participants also completed a measure of emotional breakthrough [Emotional Breakthrough Inventory (EBI)] in relation to the acute psychedelic experience. RESULTS: Bayesian t tests demonstrated overwhelming evidence for improvements in depression and wellbeing scores following the psychedelic experience. Marginal evidence was also found for a correlation between emotional breakthrough and the relevant mental health improvements. CONCLUSION: These findings provide supportive evidence for positive psychological aftereffects of a psychedelic experience that are relevant to the treatment of EDs. It is hoped that this will encourage further research and will bolster initiatives to directly examine the safety and efficacy of psychedelic assisted therapy as a treatment of EDs in future clinical trials. LEVEL OF EVIDENCE: Level III, cohort study.
Authors: A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller Journal: Biol Psychiatry Date: 2003-09-01 Impact factor: 13.382
Authors: Ruth Tennant; Louise Hiller; Ruth Fishwick; Stephen Platt; Stephen Joseph; Scott Weich; Jane Parkinson; Jenny Secker; Sarah Stewart-Brown Journal: Health Qual Life Outcomes Date: 2007-11-27 Impact factor: 3.186
Authors: Jan Alexander de Vos; Andrea LaMarre; Mirjam Radstaak; Charlotte Ariane Bijkerk; Ernst T Bohlmeijer; Gerben J Westerhof Journal: J Eat Disord Date: 2017-11-01
Authors: Eline C H M Haijen; Mendel Kaelen; Leor Roseman; Christopher Timmermann; Hannes Kettner; Suzanne Russ; David Nutt; Richard E Daws; Adam D G Hampshire; Romy Lorenz; Robin L Carhart-Harris Journal: Front Pharmacol Date: 2018-11-02 Impact factor: 5.810
Authors: Roberta Murphy; Hannes Kettner; Rick Zeifman; Bruna Giribaldi; Laura Kartner; Jonny Martell; Tim Read; Ashleigh Murphy-Beiner; Michelle Baker-Jones; David Nutt; David Erritzoe; Rosalind Watts; Robin Carhart-Harris Journal: Front Pharmacol Date: 2022-03-31 Impact factor: 5.810
Authors: John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane Journal: Front Psychiatry Date: 2021-12-17 Impact factor: 4.157
Authors: Victoria Amalie Nygart; Lis Marie Pommerencke; Eline Haijen; Hannes Kettner; Mendel Kaelen; Erik Lykke Mortensen; David John Nutt; Robin Lester Carhart-Harris; David Erritzoe Journal: J Psychopharmacol Date: 2022-08 Impact factor: 4.562
Authors: Robin L Carhart-Harris; Anne C Wagner; Manish Agrawal; Hannes Kettner; Jerold F Rosenbaum; Adam Gazzaley; David J Nutt; David Erritzoe Journal: J Psychopharmacol Date: 2021-04-22 Impact factor: 4.153